KR20230048501A - {2-[3-사이클로헥실-3-(트랜스-4-프로폭시-사이클로헥실)-우레이도]-티아졸-5-일설파닐}-아세트산의 결정형 및 그의 용도 - Google Patents
{2-[3-사이클로헥실-3-(트랜스-4-프로폭시-사이클로헥실)-우레이도]-티아졸-5-일설파닐}-아세트산의 결정형 및 그의 용도 Download PDFInfo
- Publication number
- KR20230048501A KR20230048501A KR1020237000609A KR20237000609A KR20230048501A KR 20230048501 A KR20230048501 A KR 20230048501A KR 1020237000609 A KR1020237000609 A KR 1020237000609A KR 20237000609 A KR20237000609 A KR 20237000609A KR 20230048501 A KR20230048501 A KR 20230048501A
- Authority
- KR
- South Korea
- Prior art keywords
- crystalline form
- xrpd pattern
- peaks
- cyclohexyl
- theta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063035994P | 2020-06-08 | 2020-06-08 | |
| US63/035,994 | 2020-06-08 | ||
| PCT/US2021/036082 WO2021252309A1 (en) | 2020-06-08 | 2021-06-07 | Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230048501A true KR20230048501A (ko) | 2023-04-11 |
Family
ID=78846441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237000609A Pending KR20230048501A (ko) | 2020-06-08 | 2021-06-07 | {2-[3-사이클로헥실-3-(트랜스-4-프로폭시-사이클로헥실)-우레이도]-티아졸-5-일설파닐}-아세트산의 결정형 및 그의 용도 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4161639A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023530785A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230048501A (cg-RX-API-DMAC7.html) |
| CN (2) | CN116056760A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021289591A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3181665A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2022015524A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021252309A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3093025A1 (en) | 2018-06-12 | 2019-12-19 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| US12391658B2 (en) | 2020-02-18 | 2025-08-19 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| US12479808B2 (en) | 2020-06-08 | 2025-11-25 | Vtv Therapeutics Llc | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0506662B8 (pt) * | 2004-01-06 | 2021-05-25 | Novo Nordisk As | compostos ativadores de glucoquinase |
| PT2576524T (pt) * | 2010-05-26 | 2017-11-17 | Vtv Therapeutics Llc | Resumo |
| IN2014DN09554A (cg-RX-API-DMAC7.html) * | 2012-05-17 | 2015-07-17 | Transtech Pharma Llc | |
| CA2903433A1 (en) * | 2013-03-04 | 2014-09-12 | Vtv Therapeutics Llc | Stable glucokinase activator compositions |
| HK1213197A1 (zh) * | 2013-03-04 | 2016-06-30 | Vtv治疗有限责任公司 | 包括葡糖激酶活化劑的固體組合物及其製備和使用方法 |
| DK3556354T3 (da) * | 2016-12-15 | 2025-08-04 | Hua Medicine Shanghai Ltd | Oral fremstilling af en glucokinaseaktivator og fremgangsmåde til fremstilling deraf |
-
2021
- 2021-06-07 CA CA3181665A patent/CA3181665A1/en active Pending
- 2021-06-07 CN CN202180056233.1A patent/CN116056760A/zh active Pending
- 2021-06-07 WO PCT/US2021/036082 patent/WO2021252309A1/en not_active Ceased
- 2021-06-07 KR KR1020237000609A patent/KR20230048501A/ko active Pending
- 2021-06-07 EP EP21821691.9A patent/EP4161639A4/en active Pending
- 2021-06-07 JP JP2023519156A patent/JP2023530785A/ja active Pending
- 2021-06-07 MX MX2022015524A patent/MX2022015524A/es unknown
- 2021-06-07 CN CN202511373032.0A patent/CN121202809A/zh active Pending
- 2021-06-07 AU AU2021289591A patent/AU2021289591A1/en active Pending
-
2022
- 2022-12-06 MX MX2026000786A patent/MX2026000786A/es unknown
-
2026
- 2026-03-04 JP JP2026034319A patent/JP2026108667A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2026000786A (es) | 2026-03-02 |
| CN116056760A (zh) | 2023-05-02 |
| JP2026108667A (ja) | 2026-06-30 |
| US20230219910A1 (en) | 2023-07-13 |
| EP4161639A4 (en) | 2024-01-17 |
| AU2021289591A1 (en) | 2023-01-19 |
| MX2022015524A (es) | 2023-03-22 |
| CA3181665A1 (en) | 2021-12-16 |
| WO2021252309A1 (en) | 2021-12-16 |
| JP2023530785A (ja) | 2023-07-19 |
| EP4161639A1 (en) | 2023-04-12 |
| CN121202809A (zh) | 2025-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6114849B2 (ja) | プリン誘導体の結晶性形態 | |
| EP2989084B1 (en) | Crystal modifications of elobixibat | |
| KR20250030524A (ko) | (s)-2-(((s)-6,8-디플루오로-1,2,3,4-테트라하이드로나프탈렌-2-일)아미노)-n-(1-(2-메틸-1-(네오펜틸아미노)프로판-2-일)-1h-이미다졸-4-일)펜탄아미드의고체 상태 형태 및 이의 용도 | |
| EP4010322B1 (en) | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof | |
| AU2016269524A1 (en) | Glycopyrrolate salts | |
| AU2021289591A1 (en) | Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof | |
| US12479808B2 (en) | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof | |
| JP2024001167A (ja) | ノボビオシン類似体とプロリンとの共結晶形態 | |
| KR20240119299A (ko) | 피라졸로[3,4-d]피리미딘 화합물의 고체 형태 | |
| WO2026008074A1 (zh) | 补体因子b抑制剂的晶型、其制备方法及用途 | |
| HK40131995A (en) | Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and uses thereof | |
| WO2024169896A1 (zh) | 一种苯并氮杂芳环衍生物的盐、晶型及其在医药上的应用 | |
| KR102963137B1 (ko) | 벤조티아졸 화합물의 약제학적 염, 다형체 및 이들의 제조 방법 | |
| HK40119275A (en) | Co-crystal forms of a novobiocin analog and proline | |
| HK40111611B (en) | Acidic salt or crystal form of nitrogen-containing fused ring derivative inhibitor, and preparation method therefor and use thereof | |
| HK40111611A (zh) | 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用 | |
| HK40074778B (en) | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof | |
| HK40074778A (en) | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof | |
| HK1221224B (en) | Crystal modifications of elobixibat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |